Butterfly Skin: Caring for Patients with Epidermolysis Bullosa | Ep.1: Health Compass Podcast

Why It Matters

Gene‑therapy advances could transform a life‑limiting disease into a manageable condition, reshaping treatment standards for rare skin disorders and informing broader regenerative medicine strategies.

Key Takeaways

• EB causes painful blisters from minimal friction
• Stanford researchers are launching first EB gene‑therapy trials
• Dr. Tang focuses on genomic analysis and clinical translation
• Dr. Marinkovich bridges inflammatory skin disease research and patient care

Pulse Analysis

Epidermolysis bullosa (EB) remains one of the most debilitating rare skin disorders, affecting roughly 1 in 20,000 births worldwide. Characterized by fragile skin that tears at the slightest friction, patients endure chronic wounds, infections, and severe pain, leading to reduced quality of life and high medical costs. Understanding the genetic mutations that compromise skin integrity has been a research priority, yet therapeutic options have been limited to wound care and symptom management, leaving a critical unmet need for disease‑modifying treatments.

Stanford Medicine’s dermatology team, led by Dr. Jean Tang and Dr. Peter Marinkovich, is now translating that molecular insight into actionable therapies. Leveraging CRISPR‑based editing and viral vector delivery, their early‑phase gene‑therapy trials aim to replace defective collagen genes directly within patients’ skin cells. By integrating genomic sequencing, patient‑derived organoids, and rigorous clinical trial design, the program seeks not only to halt blister formation but also to promote durable skin regeneration. The initiative marks the first time a gene‑editing approach has moved from bench to bedside for EB, positioning Stanford as a pioneer in rare‑disease translational research.

Beyond the immediate clinical promise, these advances signal a broader shift in how rare genetic conditions are tackled. Successful EB gene therapy could establish a scalable model for other collagen‑related disorders and inform regulatory pathways for similar interventions. Moreover, the podcast amplifies patient and caregiver voices, highlighting the importance of community engagement in trial recruitment and outcome prioritization. As data emerge, stakeholders—from insurers to biotech investors—will watch closely, recognizing that breakthroughs in EB may catalyze a new era of precision dermatology and regenerative medicine.

Original Description

Epidermolysis bullosa, often called “butterfly skin,” makes even the smallest touch painful. In this episode, we explore the courage of patients and families living with EB, and how Stanford clinician-researchers are helping turn decades of research into the first gene therapies that offer real hope.

Jean Tang, MD, PhD, professor of dermatology at Stanford Medicine, is a physician-scientist focused on rare genetic skin diseases and skin cancer. Her research centers on epidermolysis bullosa (EB) and basal cell carcinoma, employing clinical trials, genomic analysis, and translational approaches. Clinically, she cares for patients with non-melanoma skin cancers and genetic skin disorders and participates in efforts to improve prevention and care for these conditions. She earned her MD and PhD in basic science from Stanford University, where she also completed her dermatology residency.

M. Peter Marinkovich, MD, is an associate professor of dermatology at Stanford Medicine and a faculty member of the Program in Epithelial Biology and the Stanford Cancer Biology Program. He directs the Stanford Bullous Disease and Psoriasis Clinics and serves as an attending dermatologist at the VA Palo Alto Medical Center. His research centers on understanding the pathogenesis and therapy of epidermolysis bullosa, autoimmune blistering diseases, psoriasis, and skin cancer. His clinical work bridges complex inflammatory skin disorders with translational research to advance treatment options. He completed his residency at Oregon Health and Science University and completed his fellowship at Shriners Hospitals for Children.

Health Compass podcast: https://stan.md/health-compass

Stanford Medicine advances human health through world-class biomedical research, education and patient care. Bringing together the resources of Stanford University School of Medicine, Stanford Health Care and Lucile Packard Children's Hospital, Stanford Medicine is committed to training future leaders in biomedicine and translating the latest discoveries into new ways to prevent, diagnose and treat disease.

The Stanford Medicine YouTube channel is a curated collection of contributions from our School of Medicine departments, divisions, students, and the community. Our diverse content includes coverage of events, presentations, lectures, and associated stories about the people of Stanford Medicine.